Tag Archives: Tendering and procurement

Policy Analysis and Guidance: Guangdong Province’s Volume-Based Drug Procurement Initiative

Guangdong Province’s Drug Exchange Center has issued a notice outlining the implementation details of the centralized volume-based procurement initiative for medications such as Apixaban tablets. This policy, effective from April 1, 2025, to December 31, 2025, aims to streamline drug procurement processes, enhance supply chain stability, and ensure quality assurance across healthcare institutions.

Key Policy Measures

Tripartite Contract Signing
- Process: Medical institutions must use CA certificates to log into Guangdong’s tender and procurement subsystem to initiate tripartite contracts. Detailed operational guidance is available on the official website.
- Timeline: Contracts must be completed promptly after initiation by medical institutions, with drug manufacturers and distributors required to log in and finalize agreements without delay.
Quality and Supply Responsibility
- Accountability: Drug manufacturers are designated as the primary responsible parties for ensuring the quality and timely delivery of medications. They must guarantee coverage of all participating healthcare institutions across the province.
- Compliance: Selected manufacturers must adhere to agreed-upon procurement volumes and ensure uninterrupted supply chains.
Procurement Volume Negotiation
- Flexibility: For designated social healthcare institutions, procurement volumes will be determined through negotiations between supply and demand parties, allowing for tailored agreements.

Policy Orientation and Industry Implications
This initiative reflects Guangdong’s strategic focus on:

Cost Efficiency: Reducing drug prices through centralized procurement while maintaining quality standards.
Supply Chain Integrity: Ensuring uninterrupted medication supply to healthcare facilities across the province.
Transparency: Promoting clear contractual agreements and accountability mechanisms.

Conclusion
Guangdong’s volume-based procurement framework sets a benchmark for regional drug management, emphasizing efficiency, quality, and accessibility. Stakeholders, including manufacturers, distributors, and healthcare providers, should align their operations with these guidelines to optimize compliance and patient outcomes.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1906642648857317376

Policy Analysis and Guidance: Guangdong Province’s Ninth Batch of National Centralized Drug Procurement Renewal

Guangdong Province’s Drug Exchange Center has issued a notice regarding the renewal of the ninth batch of national centralized drug procurement for the second procurement year, effective from March 30, 2025, to March 29, 2026. This policy aims to ensure the continuity of drug supply, maintain quality standards, and streamline procurement processes across healthcare institutions.

Key Policy Measures

Viewing Contracted Procurement Volumes
- Process: Medical institutions and selected enterprises can use CA certificates to log into Guangdong’s tender and procurement subsystem to view contracted procurement volumes. This transparency helps in planning and managing drug distribution efficiently.
Tripartite Contract Signing
- Procedure: Medical institutions must initiate tripartite contracts through the subsystem, with detailed operational guidance available on the official website. Timely contract completion by all parties is crucial to ensure smooth implementation.
Quality and Supply Assurance
- Responsibility: Drug manufacturers are held accountable for the quality and timely supply of medications. They must ensure coverage across all participating healthcare institutions in the province, emphasizing reliability in the supply chain.

Policy Orientation and Industry Implications
The renewal initiative underscores Guangdong’s commitment to:

Supply Stability: Ensuring uninterrupted drug supply to healthcare facilities.
Quality Control: Maintaining high standards for drug quality through clear accountability.
Efficiency: Streamlining procurement processes to enhance operational effectiveness.

Conclusion
Guangdong’s approach to centralized drug procurement renewal sets a precedent for regional pharmaceutical management, emphasizing reliability, quality, and efficiency. Stakeholders should adhere to these guidelines to optimize compliance and ensure patient access to essential medications.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1905839740230307840

Policy Analysis and Guidance: Shanghai Announces Second Supply and Incomplete Specification Enterprises for National Drug Procurement

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released a notice announcing the determination of second supply and incomplete specification supply enterprises for the tenth batch of national centralized drug procurement. This initiative aims to ensure the stability of drug supply and adaptability to market dynamics, reflecting Shanghai’s commitment to optimizing its centralized procurement system.

Key Policy Highlights

Second Supply and Incomplete Specification Enterprises
- Purpose: To address market gaps and ensure uninterrupted drug supply.
- Criteria: Determined based on market share and economic factors.
Market Dynamics Adaptation
- Flexibility: Provides flexibility in responding to market changes and supply chain disruptions.
Attachment Details
- Lists: Includes detailed lists of second supply and incomplete specification supply drugs for reference by relevant stakeholders.

Policy Orientation and Industry Implications
The announcement reflects Shanghai’s strategic focus on:

Supply Chain Resilience: Ensuring continuous drug availability through diversified supply sources.
Market Adaptability: Adapting procurement strategies to meet evolving market conditions.
Transparency: Enhancing clarity and accessibility of procurement information for stakeholders.

Conclusion
Shanghai’s approach to determining second supply and incomplete specification enterprises underscores its commitment to maintaining a stable and responsive pharmaceutical market. This policy supports the reliability of the centralized procurement system and ensures patient access to essential medications. Stakeholders should stay informed of these updates to maintain operational efficiency and compliance.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2025/03/26/16522.shtml